| Titolo |
Pubblicato in |
Anno |
| Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia |
EXPERT OPINION ON PHARMACOTHERAPY |
2020 |
| Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry |
INTERNATIONAL JOURNAL OF CARDIOLOGY |
2020 |
| Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features |
ATHEROSCLEROSIS |
2020 |
| ApoCIII: A multifaceted protein in cardiometabolic disease |
METABOLISM, CLINICAL AND EXPERIMENTAL |
2020 |
| Familial combined hypolipidemia: Angiopoietin-like protein-3 deficiency |
CURRENT OPINION IN LIPIDOLOGY |
2020 |
| Autosomal recessive hypercholesterolemia: update for 2020 |
CURRENT OPINION IN LIPIDOLOGY |
2020 |
| How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia |
ATHEROSCLEROSIS SUPPLEMENTS |
2020 |
| High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects |
DIABETES/METABOLISM RESEARCH AND REVIEWS |
2020 |
| Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State |
ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY |
2019 |
| Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity |
PEDIATRIC RESEARCH |
2019 |
| A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large family |
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS |
2019 |
| Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease |
LIVER INTERNATIONAL |
2019 |
| Variation of PEAR1 DNA methylation influences platelet and leukocyte function. |
CLINICAL EPIGENETICS |
2019 |
| Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes |
ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY |
2019 |
| Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society Task Force Consensus Statement |
THE LANCET DIABETES & ENDOCRINOLOGY |
2019 |
| Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2019 |
| Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome |
NEW ENGLAND JOURNAL OF MEDICINE |
2019 |
| ZBTB12 DNA methylation is associated with coagulation- and inflammation-related blood cell parameters: Findings from the Moli-family cohort |
CLINICAL EPIGENETICS |
2019 |
| Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles |
JOURNAL OF THE ENDOCRINE SOCIETY |
2019 |
| PCSK9 inhibitors (PCSK9i), a new opportunity for cardiovascular prevention: Clinical and regulatory aspects and access to therapy |
RECENTI PROGRESSI IN MEDICINA |
2019 |
